Summary
Chromosome 17 alterations are found in more cancers than those of any other chromosome, and frequently involve the p53 gene on 17p13. The aim of this study was to identify the correlations between the presence of loss of heterozygosity (LOH) and microsatellite instability (MI) on chromosome 17p13 in patients with cervical cancer and the patients’ response to radiotherapy. A total of 50 patients were treated with definitive radiotherapy. We performed biopsies and took specimens from the tumour and venous blood of all patients. Tumour and normal DNAs were analysed by polymerase chain reaction for genetic losses and instability at three polymorphic microsatellite loci mapped to 17p13. Nineteen of the 50 tumours (38%) displayed a genetic alteration (GA) on 17p13, 16 (32%) were found to have LOH, and three (6%) showed MI. The sizes of the tumours of the GA-positive patients were significantly greater than those of the GA-negative patients (P = 0.009). The mean tumour diameter of all patients was 6 ± 2.4 cm. We divided the patients into those with tumours smaller than 6 cm in diameter (n = 26) and those with tumours equal to or greater than 6 cm in diameter (n = 24). The former group survived significantly longer compared to the latter group (P = 0.0002). Among the patients with < 6 cm tumours, all six GA-positive patients are alive with no evidence of disease (NED), whereas of the 20 GA-negative patients, 18 have NED and two are alive with disease (AWD) or suffered cancer-caused death (CD). Thus, there was no correlation between GA and radiotherapy response in the tumours smaller than 6 cm. However, among the patients with ≥ 6 cm tumours, two of the GA-positive patients have NED and 11 are AWD/CD, whereas seven of the GA-negative patients have NED and four are AWD/CD. Among the patients with ≥ 6 cm tumours, the response to radiotherapy of the GA-positive patients were significantly poorer than those of the GA-negative patients (P = 0.02). In addition, the GA-negative patients survived significantly longer compared to the GA-positive patients (P = 0.026). The results of this study suggest that GA increases with tumour growth. Improved success in the management of bulky cervical cancer requires a better understanding of its biological behaviour.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aas, T, Børresen, AL, Geisler, S, Smith-Sørensen, B, Johnsen, H, Varhaug, JE, Akslen, LA & Lønning, PE (1996). Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811–814.
Ahnen, DJ, Feigl, P, Quan, G, Fenoglio Preiser, C, Lovato, LC, Bunn, PA Jr, Stemmerman, G, Wells, JD, Macdonald, JS & Meyskens, FL Jr (1998). Ki-ras mutation and p53 overexpression predict the clinical behaviour of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58: 1149–1158.
Atkin, NB, Baker, MC & Fox, MF (1990). Chromosome changes in 43 carcinomas of the cervix uteri. Cancer Genet Cytogenet 44: 229–241.
Bronner, CE, Baker, SM, Morrison, PT, Warren, G, Smith, LG, Lescoe, MK, Kane, M, Earabino, C, Lipford, J, Lindblom, A, Tannergård, P, Bollag, RJ, Godwin, AR, Ward, DC, Nordenskjøld, M, Fishel, R, Kolodner, R & Liskay, RM (1994). Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368: 258–261.
Burger, RA, Monk, BJ, Kurosaki, T, Anton Culver, H, Vasilev, SA, Berman, ML & Wilczynski, SP (1996). Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 88: 1361–1368.
Butz, K, Shahabeddin, L, Geisen, C, Spitkovsky, D, Ullmann, A & Hoppe-Seyler, F (1995). Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10: 927–936.
Caron, H (1995). Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med-Pediatr-Oncol 24: 215–221.
Chang, F, Syrjänen, S & Syrjänen, K (1995). Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13: 1009–1022.
Chen, TM, Chen, CA, Hsieh, CY, Chang, DY, Chen, YU & Defendi, V (1993). The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells. Oncogene 8: 1511–1518.
Dib, C, Faure, S, Fizames, C, Samson, D, Drouot, N, Vignal, A, Millasseau, P, Marc, S, Hazan, J, Seboun, E, Lathrop, M, Gyapay, G, Morissette, J & Weissenbach, J (1996). A comprehensive genetic map of the human genome based on 5, 264 microsatellite. Nature 380: 152–154.
FIGO (1979). Annual Report on the Results of Treatment in Carcinoma of the Uterus, Vagina, and Ovary, vol. 16, FIGO: Radiumhemmet, Sweden
Fishel, R, Lescoe, MK, Rao, MR, Copeland, NG, Jenkins, NA, Garber, J, Kane, M & Kolodner, R (1993). The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027–1038.
Gehan, EA (1965). A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52: 203–223.
Harima, Y, Harima, K, Shikata, N, Oka, A, Ohnishi, T & Tanaka, Y (1998). Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol in press
Higgins, GD, Davy, M, Roder, D, Uzelin, DM, Philips, GE & Burrell, CJ (1991). Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet 338: 910–913.
ICRU Report No, 38 (1985). Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology. International Commission of Radiation Units and Measurements: Bethesda, MD
Iwasaka, A, Nieman, P, Lehtinen, M & Paavonen, J (1996). Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 77: 2275–2279.
Jones, MH & Nakamura, Y (1992). Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms. Oncogene 7: 1631–1634.
Jones, MH, Koi, S, Fujimoto, I, Hasumi, K, Kato, K & Nakamura, Y (1994). Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p. Genes Chromosomes Cancer 9: 119–123.
Kaplan, EL & Meier, P (1958). Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Kapp, DS & Giaccia, A (1996). New direction for radiation biology research in cancer of the uterine cervix. J Natl Cancer Inst 21: 131–138.
Kawana, T (1995). Human papilloma virus and cervical cancer. Jpn J Cancer Chemother 22: 711–717.
King, LA, Tase, T, Twiggs, LB, Okagaki, T, Savage, JE, Adcock, LL, Prem, KA & Carson, LF (1989). Prognostic significance of the presence of human papillomavirus DNA in patients with invasive carcinoma of the cervix. Cancer 63: 897–900.
Kohno, T, Takayama, H, Hamaguchi, M, Takano, H, Yamaguchi, N, Tsuda, H, Hirohashi, S, Vissing, H, Shimizu, M, Oshimura, M & Yokota, J (1993). Deletion mapping of chromosome 3p in human uterine cervical cancer. Oncogene 8: 1825–1832.
Kristensen, GB, Karlsen, F, Jenkins, A, Kaern, J, Abeler, VM & Trope, CG (1996). Human papilloma virus has no prognostic significance in cervical carcinoma. Eur J Cancer 32: 1349–1353.
Leach, FS, Nicolaides, NC, Papadopoulos, N, Liu, B, Jen, J, Parsons, R, Peltomaki, P, Sistonen, P, Aaltonen, LA, Nyström-Lahti, M, Guan, XY, Zhang, J, Meltzer, PS, Yu, JW, Kao, FT, Chen, DJ, Cerosaletti, KM, Fournier, REK, Todd, S, Lewis, T, Leach, RJ, Naylor, SL, Weissenbach, J, Mecklin, JP, Järvinen, H, Petersen, GM, Hamilton, SR, Green, L, Jass, J, Watson, P, Lynch, HT, Trent, JM, Chapelle, A, Kinzler, KW & Vogelstein, B (1993). Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75: 1215–1225.
Li, X, Lee, NK, Ye, YW, Waber, PG, Schweitzer, C, Cheng, QC & Nisen, PD (1994). Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst 86: 1524–1529.
Lowe, SW, Schmitt, EM, Smith, SW & Osborne, BA (1993). p53 is required for radiation–induced apoptosis in mouse thymocytes. Nature 362: 847–849.
Lowe, SW, Bodis, S, McClatchey, A, Remington, L, Ruley, HE, Fisher, DE, Housman, DE & Jacks, T (1994). P53 status and the efficacy of cancer therapy in vivo. Science 266: 807–810.
Lynch, HT, Smyrk, TC, Watson, P, Lanspa, SJ, Lynch, JF, Lynch, PM, Cavalieri, RJ & Boland, CR (1993). Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104: 1535–1549.
Marshall, CJ (1991). Tumor suppressor genes. Cell 64: 313–326.
Matsumoto, K, Yoshikawa, H, Taketani, Y, Yoshiike, K & Kanda, T (1997). Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. Jpn J Cancer Res 88: 369–375.
Mitra, AB, Murty, VV, Li, RG, Pratap, M, Luthra, UK & Chaganti, RS (1994). Allelotype analysis of cervical carcinoma. Cancer Res 54: 4481–4487.
Mitra, AB, Murty, VV, Singh, V, Li, RG, Pratap, M, Sodhani, P, Luthra, UK & Chaganti, RS (1995). Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J Natl Cancer I 87: 742–745.
Mullokandov, MR, Kholodilov, NG, Atkin, NB, Burk, RD, Johnson, AB & Klinger, HP (1996). Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 56: 197–205.
Nicolaides, NC, Papadopoulos, N, Liu, B, Wei, YF, Carter, KC, Ruben, SM, Rosen, CA, Haseltine, WA, Fleischmann, RD, Fraser, CM, Adams, MD, Venter, JC, Dunlop, MG, Hamilton, SR, Petersen, GM, Chapelle, A, Vogelstein, B & Kinzler, KW (1994). Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371: 75–80.
Papadopoulos, N, Nicolaides, NC, Wei, YF, Ruben, SM, Carter, KC, Rosen, CA, Haseltine, WA, Fleischmann, RD, Fraser, CM, Adams, MD, Venter, JC, Hamilton, SR, Petersen, GM, Watson, P, Lynch, HT, Peltomäki, P, Mecklin, JP, Chapelle, A, Kinzler, KW & Vogelstein, B (1994). Mutation of a mutL homolog in hereditary colon cancer. Science 263: 1625–1629.
Park, DJ, Wilczynski, SP, Paquette, RL, Miller, CW & Koeffler, HP (1994). p53 mutations in HPV-negative cervical carcinoma. Oncogene 9: 205–210.
Srivatsan, ES, Misra, BC, Venugopalan, M & Wilczynski, SP (1991). Loss of heterozygosity for alleles on chromosome 11 in cervical carcinoma. Am J Hum Genet 49: 868–877.
Scheffner, M, Werness, BA, Huibregtse, JM, Levine, AJ & Howley, PM (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136.
Schiffman, MH (1992). Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 84: 394–398.
Pontén, J, Adami, HO, Bergström, R, Dillner, J, Friberg, LG, Gustafsson, L, Miller, AB, Parkin, DM, Sparén, P & Trichopoulos, D (1995). Strategies for global control of cervical cancer. Int J Cancer 60: 1–26.
Virostek, LJ, Kim, RY, Spencer, SA, Meredith, RF, Jennelle, RL, Soong, SJ & Salter, MM (1996). Postsurgical recurrent carcinoma of the cervix: reassessment and results of radiation therapy options. Radiology 201: 559–563.
Yokota, J, Mori, N, Akiyama, T, Shimosato, Y, Sugimura, T & Terada, M (1989). Multiple genetic alterations in small-cell lung carcinoma. Princess Takamatsu Symp 20: 43–48.
Yoshikawa, H, Kawana, T, Kitagawa, K, Mizuno, M, Yoshikura, H & Iwamoto, A (1990). Amplification and typing of multiple cervical cancer-associated human papillomavirus DNAs using a single pair of primers. Int J Cancer 45: 990–992.
zur Hausen, H & E de, Villier (1994). Human papillomavirus. Annu Rev Microbiol 48: 427–447.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Harima, Y., Shirahama, S., Harima, K. et al. Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer. Br J Cancer 81, 108–113 (1999). https://doi.org/10.1038/sj.bjc.6690658
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690658
Keywords
This article is cited by
-
Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents
Cancer and Metastasis Reviews (2008)
